{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T14:10:33Z","timestamp":1793801433691,"version":"4.6.1"},"reference-count":82,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T00:00:00Z","timestamp":1746489600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cytomegalovirus (CMV) infection is a leading complication following hematopoietic stem cell transplant (HSCT) and solid organ transplant (SOT). Virus-specific T cells (VSTs) have been used for the prophylaxis and treatment of CMV infections. We conducted a scoping review to catalogue and characterize the existing literature.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Systematic searches were performed in collaboration with an expert librarian. Inclusion criterion was the use of CMV-VST for prophylaxis or treatment in HSCT and SOT patients. Major exclusion criteria were case reports and series with &amp;lt;5 cases. Databases were queried from inception to 31 May 2024. Of the 2587 identified abstracts, full text review was performed on 92 articles, and 67 studies underwent final data extraction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Most studies were in the HSCT population. The CMV infection rate was 28% (interquartile range [IQR], 14%\u201344%) when CMV-VSTs were used as prophylaxis. Response rates for non\u2013refractory and\/or resistant (R\/R) infections and R\/R infections in HSCT patients were 98% (IQR, 70%\u2013100%) and 70% (IQR, 56%\u201388%), respectively. Four studies included SOT patients with R\/R infections, demonstrating a response rate of 15%\u201364%. Variables including donor\/recipient serostatus and antiviral use were heterogeneously reported, and various definitions of CMV infection and response were used. CMV-VSTs were well-tolerated with minimal adverse events reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>CMV-VSTs are more commonly used in HSCT patients with limited data in SOT patients, and differential reporting of key variables precludes extrapolation. A standardized registry should be considered for future studies with additional focus on the optimal dosing, timing, and interaction with concurrent antivirals.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cid\/ciaf232","type":"journal-article","created":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T09:20:40Z","timestamp":1746177640000},"page":"e218-e228","source":"Crossref","is-referenced-by-count":11,"title":["Virus-Specific T-Cell Therapy for Prophylaxis and Treatment of Cytomegalovirus Infections After Transplantation: a Scoping Review"],"prefix":"10.1093","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4555-9372","authenticated-orcid":false,"given":"Jollee S T","family":"Fung","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, University of British Columbia , Vancouver, British Columbia ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4173-5858","authenticated-orcid":false,"given":"Robert C","family":"Wright","sequence":"additional","affiliation":[{"name":"Department of Surgery, University of British Columbia , Vancouver, British Columbia ,","place":["Canada"]},{"name":"Childhood Diseases, BC Children's Hospital Research Institute , Vancouver, British Columbia ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilpreet K","family":"Bharaj","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of British Columbia , Vancouver, British Columbia ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8078-7029","authenticated-orcid":false,"given":"Amenah","family":"Alghamdi","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Internal Medicine, King Abdulaziz University , Jeddah ,","place":["Saudi Arabia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Hesson","sequence":"additional","affiliation":[{"name":"Welch Medical Library, Johns Hopkins University , Baltimore, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1460-7287","authenticated-orcid":false,"given":"Jean-S\u00e9bastien","family":"Delisle","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, H\u00f4pital Maisonneuve-Rosemont , Montr\u00e9al, Quebec ,","place":["Canada"]},{"name":"Department of Medicine, Universit\u00e9 de Montr\u00e9al , Montr\u00e9al, Quebec ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorne","family":"Schweitzer","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, McGill University Health Centre , Montr\u00e9al, Quebec ,","place":["Canada"]},{"name":"Division of Medical Microbiology, Department of Laboratory Medicine, OPTILAB-McGill University Health Centre , Montr\u00e9al, Quebec ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7692-3619","authenticated-orcid":false,"given":"Robin K","family":"Avery","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine , Baltimore, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1725-1407","authenticated-orcid":false,"given":"Sara","family":"Belga","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, University of British Columbia , Vancouver, British Columbia ,","place":["Canada"]},{"name":"Immunity and Infection Research Centre, Vancouver Coastal Health Research Institute , Vancouver, British Columbia ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,5,6]]},"reference":[{"key":"2025110901583801400_ciaf232-B1","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.cmi.2022.07.001","article-title":"Cytomegalovirus infection in transplant recipients: newly approved additions to our armamentarium","volume":"29","author":"Khawaja","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"2025110901583801400_ciaf232-B2","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1399-0012.2006.00618.x","article-title":"Cytomegalovirus in transplantation\u2014challenging the status quo","volume":"21","author":"Fishman","year":"2007","journal-title":"Clin Transplant"},{"key":"2025110901583801400_ciaf232-B3","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s40506-021-00253-w","article-title":"CMV infection in hematopoietic stem cell transplantation: prevention and treatment strategies","volume":"13","author":"Jakharia","year":"2021","journal-title":"Curr Treat Options Infect Dis"},{"key":"2025110901583801400_ciaf232-B4","doi-asserted-by":"crossref","first-page":"521.e1","DOI":"10.1016\/j.jtct.2023.04.023","article-title":"Cytomegalovirus infection post-allogeneic stem cell transplantation: experience from a country with high seropositivity","volume":"29","author":"Iftikhar","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"2025110901583801400_ciaf232-B5","doi-asserted-by":"crossref","first-page":"e14227","DOI":"10.1111\/tid.14227","article-title":"Incidence of valganciclovir-related leukopenia and neutropenia in solid organ transplant recipients at high risk of cytomegalovirus disease","volume":"26","author":"Belga","year":"2024","journal-title":"Transpl Infect Dis"},{"key":"2025110901583801400_ciaf232-B6","doi-asserted-by":"crossref","first-page":"1321116","DOI":"10.3389\/fmicb.2023.1321116","article-title":"Anti-CMV therapy, what next? A systematic review","volume":"14","author":"Gourin","year":"2023","journal-title":"Front Microbiol"},{"key":"2025110901583801400_ciaf232-B7","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1126\/science.1352912","article-title":"Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones","volume":"257","author":"Riddell","year":"1992","journal-title":"Science"},{"key":"2025110901583801400_ciaf232-B8","doi-asserted-by":"crossref","first-page":"657144","DOI":"10.3389\/fimmu.2021.657144","article-title":"Is it feasible to use CMV-specific T-cell adoptive transfer as treatment against infection in SOT recipients?","volume":"12","author":"Garc\u00eda-R\u00edos","year":"2021","journal-title":"Front Immunol"},{"key":"2025110901583801400_ciaf232-B9","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.3389\/fimmu.2020.01694","article-title":"Cellular therapeutic approaches to cytomegalovirus infection following allogeneic stem cell transplantation","volume":"11","author":"Shafat","year":"2020","journal-title":"Front Immunol"},{"key":"2025110901583801400_ciaf232-B10","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13045-019-0701-1","article-title":"Strategies of adoptive T-cell transfer to treat refractory viral infections post allogeneic stem cell transplantation","volume":"12","author":"Kaeuferle","year":"2019","journal-title":"J Hematol Oncol"},{"key":"2025110901583801400_ciaf232-B11","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1182\/blood.2022016202","article-title":"Banking on virus-specific T cells to fulfill the need for off-the-shelf cell therapies","volume":"141","author":"Quach","year":"2023","journal-title":"Blood"},{"key":"2025110901583801400_ciaf232-B12","doi-asserted-by":"crossref","first-page":"5113","DOI":"10.1182\/blood-2013-02-486324","article-title":"Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation","volume":"121","author":"Leen","year":"2013","journal-title":"Blood"},{"key":"2025110901583801400_ciaf232-B13","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1158\/1078-0432.CCR-22-2415","article-title":"Posoleucel, an allogeneic, off-the-shelf multivirus-specific T-cell therapy, for the treatment of refractory viral infections in the post-HCT setting","volume":"29","author":"Pfeiffer","year":"2023","journal-title":"Clin Cancer Res"},{"key":"2025110901583801400_ciaf232-B14","doi-asserted-by":"crossref","first-page":"4397","DOI":"10.1182\/blood-2005-05-1775","article-title":"Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation","volume":"106","author":"Perruccio","year":"2005","journal-title":"Blood"},{"key":"2025110901583801400_ciaf232-B15","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.bcmd.2007.07.003","article-title":"Adoptive cellular therapy for cytomegalovirus infection following allogeneic stem cell transplantation using virus-specific T cells","volume":"40","author":"Mackinnon","year":"2008","journal-title":"Blood Cells Mol Dis"},{"key":"2025110901583801400_ciaf232-B16","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.bbmt.2007.02.004","article-title":"Ex vivo expansion and prophylactic infusion of CMV-pp65 peptide-specific cytotoxic T-lymphocytes following allogeneic hematopoietic stem cell transplantation","volume":"13","author":"Micklethwaite","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"2025110901583801400_ciaf232-B17","doi-asserted-by":"crossref","first-page":"3974","DOI":"10.1182\/blood-2008-06-161695","article-title":"Prophylactic infusion of cytomegalovirus-specific cytotoxic T lymphocytes stimulated with Ad5f35pp65 gene-modified dendritic cells after allogeneic hemopoietic stem cell transplantation","volume":"112","author":"Micklethwaite","year":"2008","journal-title":"Blood"},{"key":"2025110901583801400_ciaf232-B18","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1086\/648422","article-title":"Cytomegalovirus-specific T cell immunotherapy promotes restoration of durable functional antiviral immunity following allogeneic stem cell transplantation","volume":"49","author":"Peggs","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2025110901583801400_ciaf232-B19","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/cid\/ciq042","article-title":"Directly selected cytomegalovirus-reactive donor T cells confer rapid and safe systemic reconstitution of virus-specific immunity following stem cell transplantation","volume":"52","author":"Peggs","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2025110901583801400_ciaf232-B20","article-title":"Improving immune reconstitution after cord blood transplantation using ex vivo expanded virus-specific t cells: a phase I clinical study [abstract 722]","author":"Hanley"},{"key":"2025110901583801400_ciaf232-B21","doi-asserted-by":"crossref","first-page":"3745","DOI":"10.1182\/blood-2012-08-448977","article-title":"Donor-derived CMV-specific T cells reduce the requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplantation","volume":"121","author":"Blyth","year":"2013","journal-title":"Blood"},{"key":"2025110901583801400_ciaf232-B22","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.bbmt.2013.01.021","article-title":"Cytomegalovirus-specific cytotoxic T lymphocytes can be efficiently expanded from granulocyte colony-stimulating factor-mobilized hemopoietic progenitor cell products ex vivo and safely transferred to stem cell transplantation recipients to facilitate immune reconstitution","volume":"19","author":"Clancy","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"2025110901583801400_ciaf232-B23","article-title":"Multi-virus-specific T-cell therapy for patients after hematopoietic stem cell and cord blood transplantation [abstract 703]","author":"Hanley"},{"key":"2025110901583801400_ciaf232-B24","article-title":"Efficacy and safety of CMV-specific T cell line (CMVTCL) for CMV reactivations in high risk adult patients (PTS) after hematopoietic stem cell transplantation (HSCT) [abstract PH-P494]","author":"Bramanti"},{"key":"2025110901583801400_ciaf232-B25","doi-asserted-by":"crossref","article-title":"CMV\u223cIMPACT: results of a randomized controlled trial of immuno-prophylactic adoptive cellular therapy following sibling donor allogeneic HSCT [abstract 703]","author":"Peggs","DOI":"10.1182\/blood.V124.21.1109.1109"},{"key":"2025110901583801400_ciaf232-B26","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1016\/j.jcyt.2015.07.005","article-title":"Addition of varicella zoster virus-specific T cells to cytomegalovirus, Epstein-Barr virus and adenovirus tri-specific T cells as adoptive immunotherapy in patients undergoing allogeneic hematopoietic stem cell transplantation","volume":"17","author":"Ma","year":"2015","journal-title":"Cytotherapy"},{"key":"2025110901583801400_ciaf232-B27","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.jaci.2015.12.1311","article-title":"Adoptive immunotherapy for primary immunodeficiency disorders with virus-specific T lymphocytes","volume":"137","author":"Naik","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"2025110901583801400_ciaf232-B28","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1182\/bloodadvances.2019000201","article-title":"Safety and feasibility of virus-specific T cells derived from umbilical cord blood in cord blood transplant recipients","volume":"3","author":"Abraham","year":"2019","journal-title":"Blood Adv"},{"key":"2025110901583801400_ciaf232-B29","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1038\/s41375-019-0600-z","article-title":"Generation and infusion of multi-antigen-specific T cells to prevent complications early after T-cell depleted allogeneic stem cell transplantation\u2014a phase I\/II study","volume":"34","author":"Roex","year":"2020","journal-title":"Leukemia"},{"key":"2025110901583801400_ciaf232-B30","doi-asserted-by":"crossref","article-title":"Posoleucel (ALVR105), an off-the-shelf, multivirus-specific T-cell therapy, for the prevention of viral infections post-HCT: results from an open-label cohort of a phase 2 trial [abstract 704]","author":"Dadwal","DOI":"10.1182\/blood-2021-152553"},{"key":"2025110901583801400_ciaf232-B31","doi-asserted-by":"crossref","first-page":"e1249","DOI":"10.1002\/cti2.1249","article-title":"Prophylactic antigen-specific T-cells targeting seven viral and fungal pathogens after allogeneic haemopoietic stem cell transplant","volume":"10","author":"Gottlieb","year":"2021","journal-title":"Clin Transl Immunology"},{"key":"2025110901583801400_ciaf232-B32","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1182\/bloodadvances.2021006309","article-title":"Scheduled administration of virus-specific T cells for viral prophylaxis after pediatric allogeneic stem cell transplant","volume":"6","author":"Rubinstein","year":"2022","journal-title":"Blood Adv"},{"key":"2025110901583801400_ciaf232-B33","doi-asserted-by":"crossref","first-page":"1251593","DOI":"10.3389\/fimmu.2023.1251593","article-title":"Prevention of CMV\/EBV reactivation by double-specific T cells in patients after allogeneic stem cell transplantation: results from the randomized phase I\/IIa MULTIVIR-01 study","volume":"14","author":"Gerbitz","year":"2023","journal-title":"Front Immunol"},{"key":"2025110901583801400_ciaf232-B34","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1038\/s41375-023-02033-5","article-title":"Persistence of ex vivo expanded tumour and pathogen specific T-cells after allogeneic stem cell transplant for myeloid malignancies (the INTACT study)","volume":"37","author":"Jiang","year":"2023","journal-title":"Leukemia"},{"key":"2025110901583801400_ciaf232-B35","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1182\/bloodadvances.2022008219","article-title":"Outcomes following posttransplant virus-specific T-cell therapy in patients with sickle cell disease","volume":"7","author":"Kinoshita","year":"2023","journal-title":"Blood Adv"},{"key":"2025110901583801400_ciaf232-B36","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1084\/jem.20040613","article-title":"Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers","volume":"202","author":"Cobbold","year":"2005","journal-title":"J Exp Med"},{"key":"2025110901583801400_ciaf232-B37","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.humimm.2004.02.016","article-title":"Augmentation of virus-specific immunity after hematopoietic stem cell transplantation by adoptive T-cell therapy","volume":"65","author":"Peggs","year":"2004","journal-title":"Hum Immunol"},{"key":"2025110901583801400_ciaf232-B38","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1038\/mt.2013.151","article-title":"Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant","volume":"21","author":"Gerdemann","year":"2013","journal-title":"Mol Ther"},{"key":"2025110901583801400_ciaf232-B39","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1093\/cid\/ciz368","article-title":"First-line therapy with donor-derived human cytomegalovirus (HCMV)\u2013specific T cells reduces persistent HCMV infection by promoting antiviral immunity after allogenic stem cell transplantation","volume":"70","author":"Zhao","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2025110901583801400_ciaf232-B40","doi-asserted-by":"crossref","first-page":"4949","DOI":"10.1182\/bloodadvances.2022007103","article-title":"Third-party CMV- and EBV-specific T-cells for first viral reactivation after allogeneic stem cell transplant","volume":"6","author":"Jiang","year":"2022","journal-title":"Blood Adv"},{"key":"2025110901583801400_ciaf232-B41","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/ajh.26535","article-title":"Adoptive therapy with cytomegalovirus-specific T cells for cytomegalovirus infection after haploidentical stem cell transplantation and factors affecting efficacy","volume":"97","author":"Pei","year":"2022","journal-title":"Am J Hematol"},{"key":"2025110901583801400_ciaf232-B42","article-title":"Adoptive immunotherapy with antiviral CTL infusion: French clinical and virological safety survey [abstract CO-017]","author":"Petitpain"},{"key":"2025110901583801400_ciaf232-B43","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.jtct.2023.01.027","article-title":"Third-party and patient-specific donor-derived virus-specific T cells demonstrate similar efficacy and safety for management of viral infections after hematopoietic stem cell transplantation in children and young adults","volume":"29","author":"Galletta","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"2025110901583801400_ciaf232-B44","doi-asserted-by":"crossref","first-page":"e007735","DOI":"10.1136\/jitc-2023-007735","article-title":"Adoptive transfer of CMV-specific TCR-T cells for the treatment of CMV infection after haploidentical hematopoietic stem cell transplantation","volume":"12","author":"Ma","year":"2024","journal-title":"J Immunother Cancer"},{"key":"2025110901583801400_ciaf232-B45","doi-asserted-by":"crossref","first-page":"3916","DOI":"10.1182\/blood.V99.11.3916","article-title":"Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy","volume":"99","author":"Einsele","year":"2002","journal-title":"Blood"},{"key":"2025110901583801400_ciaf232-B46","doi-asserted-by":"crossref","first-page":"4360","DOI":"10.1182\/blood-2010-01-262089","article-title":"Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation","volume":"116","author":"Feuchtinger","year":"2010","journal-title":"Blood"},{"key":"2025110901583801400_ciaf232-B47","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/CJI.0b013e31824300a2","article-title":"Adoptive immunotherapy with CMV-specific cytotoxic T lymphocytes for stem cell transplant patients with refractory CMV infections","volume":"35","author":"Bao","year":"2012","journal-title":"J Immunother"},{"key":"2025110901583801400_ciaf232-B48","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1097\/CJI.0b013e31826e35f6","article-title":"Effective treatment of refractory CMV reactivation after allogeneic stem cell transplantation with in vitro-generated CMV pp65-specific CD8+ T-cell lines","volume":"35","author":"Meij","year":"2012","journal-title":"J Immunother"},{"key":"2025110901583801400_ciaf232-B49","doi-asserted-by":"crossref","article-title":"Adoptive immunotherapy with donor T cells sensitized with overlapping pentadecapeptides of the CMV-PP65 protein for the treatment of persistent CMV antigenemia following allogeneic hematopoietic stem cell transplants [abstract 723]","author":"Koehne","DOI":"10.1182\/blood.V120.21.351.351"},{"key":"2025110901583801400_ciaf232-B50","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1093\/cid\/cis625","article-title":"Rapid salvage treatment with virus-specific T cells for therapy-resistant disease","volume":"55","author":"Uhlin","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2025110901583801400_ciaf232-B51","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1016\/j.bbmt.2015.05.015","article-title":"Immunotherapy with donor T cells sensitized with overlapping pentadecapeptides for treatment of persistent cytomegalovirus infection or viremia","volume":"21","author":"Koehne","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"2025110901583801400_ciaf232-B52","doi-asserted-by":"crossref","article-title":"Administration of most closely HLA-matched multivirus-specific t cells for the treatment of EBV, CMV, ADV, HHV6, and BKV post allogeneic hematopoietic stem cell transplant [abstract 721]","author":"Omer","DOI":"10.1182\/blood.V126.23.622.622"},{"key":"2025110901583801400_ciaf232-B53","article-title":"Successful treatment of refractory CMV chorioretinitis and meningoencephalitis with adoptive transfer of third party CMVPP65 specific T-cell lines [abstract 723]","author":"Prockop"},{"key":"2025110901583801400_ciaf232-B54","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.jaci.2016.03.032","article-title":"Specific T cells for the treatment of cytomegalovirus and\/or adenovirus in the context of hematopoietic stem cell transplantation","volume":"138","author":"Creidy","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"2025110901583801400_ciaf232-B55","doi-asserted-by":"crossref","article-title":"Most closely HLA-matched third party allogeneic CMV specific T-cells generated using the cytokine capture system for the treatment of CMV infections after allogeneic stem cell transplantation [abstract 703]","author":"Oran","DOI":"10.1182\/blood.V128.22.4547.4547"},{"key":"2025110901583801400_ciaf232-B56","doi-asserted-by":"crossref","article-title":"Safety and efficacy of donor-derived virus specific cytotoxic T lymphocytes (CTL) administered in treatment for CMV\/EBV infections after allogeneic stem cell transplantation [abstract 721]","author":"Wang","DOI":"10.1182\/blood.V128.22.5744.5744"},{"key":"2025110901583801400_ciaf232-B57","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1038\/leu.2017.16","article-title":"Transfer of minimally manipulated CMV-specific T cells from stem cell or third-party donors to treat CMV infection after allo-HSCT","volume":"31","author":"Neuenhahn","year":"2017","journal-title":"Leukemia"},{"key":"2025110901583801400_ciaf232-B58","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1093\/infdis\/jix357","article-title":"Cytomegalovirus-specific T-cell transfer for refractory cytomegalovirus infection after haploidentical stem cell transplantation: the quantitative and qualitative immune recovery for cytomegalovirus","volume":"216","author":"Pei","year":"2017","journal-title":"J Infect Dis"},{"key":"2025110901583801400_ciaf232-B59","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1182\/bloodadvances.2017010223","article-title":"Long-term control of recurrent or refractory viral infections after allogeneic HSCT with third-party virus-specific T cells","volume":"1","author":"Withers","year":"2017","journal-title":"Blood Adv"},{"key":"2025110901583801400_ciaf232-B60","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/CJI.0000000000000197","article-title":"Early experience with CliniMACS prodigy CCS (IFN-gamma) system in selection of virus-specific T cells from third-party donors for pediatric patients with severe viral infections after hematopoietic stem cell transplantation","volume":"41","author":"K\u00e1llay","year":"2018","journal-title":"J Immunother"},{"key":"2025110901583801400_ciaf232-B61","article-title":"Phase I\/II clinical trial demonstrates feasibility, safety and effectivity of CMV-Pp65-specific donor T-cells for the treatment of refractory CMV reactivation after allogeneic stem cell transplantation [abstract O042]","author":"Jedema"},{"key":"2025110901583801400_ciaf232-B62","article-title":"Viral-specific T cell infusions for refractory viral infections after allogeneic stem cell transplantation [abstract P323]","author":"Lozano"},{"key":"2025110901583801400_ciaf232-B63","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1182\/bloodadvances.2020002735","article-title":"Adoptive therapy with CMV-specific cytotoxic T lymphocytes depends on baseline CD41 immunity to mediate durable responses","volume":"5","author":"Fabrizio","year":"2021","journal-title":"Blood Adv"},{"key":"2025110901583801400_ciaf232-B64","doi-asserted-by":"crossref","article-title":"The safety and efficacy of targeted virus specific cytotoxic T-lymphocytes (VST) manufactured by the IFN-\u03b3 cytokine capture system (CCS) for the treatment of refractory adenovirus (ADV), cytomegalovirus (CMV), Epstein Barr virus (EBV) and BK virus (BKV) in children, adolescents and young adults (CAYA) after allogenic hematopoietic stem cell transplantation (allo-HSCT), solid organ transplantation (SOT), or with primary immunodeficiency (PID) (IND#17449) [abstract 95]","author":"Flower","DOI":"10.1016\/j.bbmt.2019.12.220"},{"key":"2025110901583801400_ciaf232-B65","article-title":"Third-party virus-specific T-cell infusion for treatment of refractory viral infections: interim results from PBMTC SUP1701 [abstract 121]","author":"Keller"},{"key":"2025110901583801400_ciaf232-B66","article-title":"Safety and efficacy of virus-specific cytotoxic T-lymphocytes manufactured by the IFN-gamma cytokine capture system for the treatment of refractory adenovirus, cytomegalovirus, Epstein Barr virus, and BK virus infections in children, adolescents and young adults after allogeneic hematopoietic stem cell transplantation, solid organ transplantation, or with primary immunodeficiency (IND# 17449) [abstract 424]","author":"Flower"},{"key":"2025110901583801400_ciaf232-B67","doi-asserted-by":"crossref","article-title":"Viral-specific T cell therapy for cytomegalovirus infection after stem cell transplantation and generation of a third-party T-cell donor registry [abstract 704]","author":"Barba","DOI":"10.1182\/blood-2022-165943"},{"key":"2025110901583801400_ciaf232-B68","doi-asserted-by":"crossref","article-title":"A novel CMV-specific TCR-T cell therapy is effective and safe for refractory CMV infection after allogeneic hematopoietic stem cell transplantation [abstract 704]","author":"Cao","DOI":"10.1182\/blood-2021-146446"},{"key":"2025110901583801400_ciaf232-B69","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/s41423-021-00829-y","article-title":"Comparable anti-CMV responses of transplant donor and third-party CMV-specific T cells for treatment of CMV infection after allogeneic stem cell transplantation","volume":"19","author":"Pei","year":"2022","journal-title":"Cell Mol Immunol"},{"key":"2025110901583801400_ciaf232-B70","doi-asserted-by":"crossref","first-page":"1027341","DOI":"10.3389\/fcimb.2022.1027341","article-title":"Features of cytomegalovirus infection and evaluation of cytomegalovirus-specific T cells therapy in children's patients following allogeneic hematopoietic stem cell transplantation: a retrospective single-center study","volume":"12","author":"Ruan","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"key":"2025110901583801400_ciaf232-B71","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/s41409-021-01499-0","article-title":"Cytomegalovirus (CMV)\u2013specific cytotoxic T lymphocyte therapy resolve CMV diseases and refractory CMV infections in paediatric recipients of allogeneic haematopoietic stem cell transplantation","volume":"57","author":"Wang","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"2025110901583801400_ciaf232-B72","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.3324\/haematol.2022.281996","article-title":"Automated production of specific T cells for treatment of refractory viral infections after allogeneic stem cell transplantation","volume":"108","author":"Heinz","year":"2023","journal-title":"Haematologica"},{"key":"2025110901583801400_ciaf232-B73","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1111\/bjh.19282","article-title":"Adoptive therapy with cytomegalovirus-specific cytotoxic T lymphocytes for refractory cytomegalovirus DNAemia and disease after allogeneic haematopoietic stem cell transplantation","volume":"204","author":"Jiang","year":"2024","journal-title":"Br J Haematol"},{"key":"2025110901583801400_ciaf232-B74","doi-asserted-by":"crossref","first-page":"e165476","DOI":"10.1172\/JCI165476","article-title":"Third-party cytomegalovirus-specific T cells improved survival in refractory cytomegalovirus viremia after hematopoietic transplant","volume":"133","author":"Prockop","year":"2023","journal-title":"J Clin Invest"},{"key":"2025110901583801400_ciaf232-B75","doi-asserted-by":"crossref","first-page":"3258","DOI":"10.1038\/s41467-024-47057-2","article-title":"Antiviral cellular therapy for enhancing T-cell reconstitution before or after hematopoietic stem cell transplantation (ACES): a two-arm, open label phase II interventional trial of pediatric patients with risk factor assessment","volume":"15","author":"Keller","year":"2024","journal-title":"Nat Commun"},{"key":"2025110901583801400_ciaf232-B76","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.1002\/hem3.40","article-title":"On behalf of the SFGM-TC: real-life use of third-party virus-specific T-cell transfer in immunocompromised transplanted patients","volume":"8","author":"Leroyer","year":"2024","journal-title":"Hemasphere"},{"key":"2025110901583801400_ciaf232-B77","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1093\/cid\/ciy549","article-title":"Autologous adoptive T-cell therapy for recurrent or drug-resistant cytomegalovirus complications in solid organ transplant recipients: a single-arm open-label phase I clinical trial","volume":"68","author":"Smith","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2025110901583801400_ciaf232-B78","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1016\/j.ajt.2024.04.009","article-title":"Third-party virus-specific T cells for the treatment of double-stranded DNA viral reactivation and posttransplant lymphoproliferative disease after solid organ transplant","volume":"24","author":"Khoury","year":"2024","journal-title":"Am J Transplant"},{"key":"2025110901583801400_ciaf232-B79","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1038\/s41467-024-47056-3","article-title":"Secondary bone marrow graft loss after third-party virus-specific T cell infusion: case report of a rare complication","volume":"15","author":"Keller","year":"2024","journal-title":"Nat Commun"},{"key":"2025110901583801400_ciaf232-B80","doi-asserted-by":"publisher","DOI":"10.1016\/j.idc.2023.10.001","article-title":"Updates in cytomegalovirus prevention and treatment in solid organ transplantation [manuscript published online ahead of print 20 November 2023]","author":"Doss","year":"2023","journal-title":"Infect Dis Clin North Am"},{"key":"2025110901583801400_ciaf232-B81","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1093\/cid\/ciae321","article-title":"Consensus definitions of cytomegalovirus (CMV) infection and disease in transplant patients including resistant and refractory CMV for use in clinical trials: 2024 update from the Transplant Associated Virus Infections Forum","volume":"79","author":"Ljungman","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2025110901583801400_ciaf232-B82","author":"AlloVir, Inc"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciaf232\/63069865\/ciaf232.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/81\/4\/e218\/63069865\/ciaf232.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/81\/4\/e218\/63069865\/ciaf232.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T06:58:51Z","timestamp":1762671531000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/81\/4\/e218\/8125789"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,6]]},"references-count":82,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,5,6]]},"published-print":{"date-parts":[[2025,11,6]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaf232","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10,15]]},"published":{"date-parts":[[2025,5,6]]}}}